Infliximab (Avakine) 是一种与 TNF-α 特异性结合的嵌合单克隆 IgG1 抗体。Infliximab 可阻止 TNF-α 与 TNF-α 受体 1 (TNFR1) 和 TNFR2 的相互作用。Infliximab 可用于自身免疫，慢性炎症性疾病和糖尿病神经病变的研究。
| 生物活性 |
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research. |
|---|---|
| 体外研究 |
TNF-α-treated adipocytes shows a significant 64% decrease in insulin-stimulated glucose uptake, whereas Infliximab (10 ng/mL) reverses TNF-α actions by significantly improving glucose incorporation in 3T3L1 adipocytes. Infliximab restores phosphorylation of substrate-2 and AKT by attenuating protein-tyrosine phosphatase 1B (PTP1B) activation. Infliximab ameliorates TNF-α-induced insulin resistance in 3T3L1 adipocytes in vitro by restoring the insulin signalling pathway via PTP1B inhibition. |
| 体内研究 |
A single injection of Infliximab (10 μg/g in 100 μl saline/dose ip) in diabetic TNF-α) mice leads to suppression of the increased serum TNF-α and amelioration of the electrophysiological and biochemical deficits for at least 4 weeks. The increased TNF-α mRNA expression in diabetic dorsal root ganglion is also attenuated by Infliximab.
|
| 分子量 |
145.98 kDa
|
| CAS号 |
170277-31-3
|
| 中文名称 |
英夫利昔单抗
|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| 临床试验 |
|
纯度： 90%
关注我们
获得KKL MED 最新资讯
咨询热线：
400-881-9290
Data Sheet